Sodium Hydroxide → HCID 86700383、化合物
反応式
[C:1]([O:5][C@@H:6]([C:12]1[C:36]([CH3:37])=[CH:35][C:15]2[N:16]=[C:17]([C:19]3[N:20]=[C:21]([C:25]4[CH:26]=[C:27]5[C:31](=[CH:32][CH:33]=4)[N:30]([CH3:34])[N:29]=[CH:28]5)[N:22]([CH3:24])[CH:23]=3)[S:18][C:14]=2[C:13]=1[C:38]1[CH:43]=[CH:42][C:41]([Cl:44])=[CH:40][CH:39]=1)[C:7]([O:9]CC)=[O:8])([CH3:4])([CH3:3])[CH3:2].[OH-].[Na+]>C1COCC1.O>[C:1]([O:5][C@@H:6]([C:12]1[C:36]([CH3:37])=[CH:35][C:15]2[N:16]=[C:17]([C:19]3[N:20]=[C:21]([C:25]4[CH:26]=[C:27]5[C:31](=[CH:32][CH:33]=4)[N:30]([CH3:34])[N:29]=[CH:28]5)[N:22]([CH3:24])[CH:23]=3)[S:18][C:14]=2[C:13]=1[C:38]1[CH:39]=[CH:40][C:41]([Cl:44])=[CH:42][CH:43]=1)[C:7]([OH:9])=[O:8])([CH3:4])([CH3:2])[CH3:3]参加物
反応条件
- 温度
- 30 °C
実験手順
In a 25 mL round bottom flask, (S)-ethyl 2-tert-butoxy-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-2-(1-methyl-1H-indazol-5-yl)-1H-imidazol-4-yl)benzo[d]thiazol-6-yl)acetate 15 mg, 0.024 mmol) was dissolved in THF (1.5 mL) EtOH (0.7 mL) and water (0.5 mL). Then aqueous NaOH (2 N) (0.4 mL) was added. The reaction mixture was stirred at 30° C. in oil bath for 17 h. The resulting reaction mixture was concentrated. The residue was purified on Gilson reverse phase HPLC with CH3CN and water (10 mL) to afford the product. LCMS-ESI+: calc'd for: C32H30ClN5O3S: 600.2, 602.2, 601.2 (M+H+); Found: 600.3, 602.3, 601.3 (M+H+). 1H NMR (400 MHz, CD3OD) δ 8.03 (d, J=0.8 Hz, 1H), 7.99 (dd, J=1.6, 0.8 Hz, 1H), 7.93-7.88 (m, 1H), 7.83 (s, 1H), 7.67-7.58 (m, 3H), 7.50 (dd, J=8.6, 2.3 Hz, 1H), 7.42 (ddd, J=8.3, 5.5, 2.2 Hz, 2H), 5.01 (s, 1H), 4.03 (d, J=0.7 Hz, 3H), 3.75 (s, 3H), 2.55 (s, 3H), 0.82 (s, 9H).
後処理
- customThe resulting reaction mixture
- concentrationwas concentrated
- customThe residue was purified on Gilson reverse phase HPLC with CH3CN and water (10 mL)
- customto afford the product
出典と根拠
- ORDレコード
- ord-7477109aaa9c461d957d423e0b63585e
- 出典データセット
- uspto-grants-2015_03
- 特許番号
- US08987250B2
反応ノート
読み込み中…